Clinical trials
catalyst calendar across sponsors →Studies where LUCD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 observational · 1 with posted results
Held by 6 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, GABELLI FUNDS LLC, +1 more) · FINRA short interest 8.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| CLUE: CLinical Utility Study of EsoGuardNCT06030180Clinical UtilityOpen-label · Diagnostic | Not applicable | Completed | Device: EsoGuard | Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma | 566 | 2024-12-13actual | 2025-06-27 |
| Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk PopulationNCT05778851results2025-10-30The Impact of EsoCheck/EsoGuard on Provider's Decision for Upper Endoscopy ReferralRandomized · Single-masked · ScreeningStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: EsoGuard result | Barrett Esophagus | 97 | 2024-07-31actual | 2025-10-30 |
| Lucid Registry StudyNCT05965999observationalAgreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy) | — | Unknown status | Device: EsoCheck | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 500 | 2024-06-01 | 2023-07-28 |
| Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EACNCT04295811Primary EfficacyOpen-label · Diagnostic | Not applicable | Unknown status | Device: EsoGuard (lab assay) · Diagnostic test: Esophagogastroduodenoscopy | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 470 | Dec 2023 | 2023-01-25 |
| Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BENCT04293458Primary EfficacyOpen-label · Screening | Not applicable | Completed | Device: EsoGuard | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 145 | 2022-08-22actual | 2023-01-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19